{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:46:39Z","timestamp":1786992399297,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jgo.2023.101604","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T02:25:27Z","timestamp":1693967127000},"page":"101604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study"],"prefix":"10.1016","volume":"14","author":[{"given":"Okan","family":"Avc\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakup","family":"\u0130ria\u011fa\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyy\u00fcp","family":"\u00c7avdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kubilay","family":"Karaboyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Araz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teoman","family":"\u015eakalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"De\u011ferli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"\u0130nal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birol","family":"Ocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcslih","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Sakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seher","family":"Y\u0131ld\u0131z Tacar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Zahid","family":"Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacer","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zden","family":"\u00d6zer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eda","family":"Tanr\u0131kulu \u015eim\u015fek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ersoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Karaka\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukiye","family":"Ar\u0131kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"E\u015fbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"\u00d6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"\u015eenocak Ta\u015f\u00e7\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil","family":"Molinas Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"T\u00fcrker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgut","family":"Ka\u00e7an","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan \u00c7a\u011fr\u0131","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zkan","family":"Alan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"Akba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclhan","family":"\u0130pek Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Ayd\u0131n \u0130sak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil","family":"Ta\u015fkaynatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdo\u011fan Sel\u00e7uk","family":"\u015eeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2023.101604_bb0005","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2005.05.064","article-title":"Cyclin D1 in breast cancer pathogenesis","volume":"23","author":"Arnold","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/bcr3652","article-title":"Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions","volume":"16","author":"Witkiewicz","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jgo.2023.101604_bb0015","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2023.101604_bb0020","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2023.101604_bb0025","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","article-title":"Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)","volume":"55","author":"Extermann","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jgo.2023.101604_bb0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.breast.2013.01.011","article-title":"Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy","volume":"22","author":"Aaldriks","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.jgo.2023.101604_bb0040","article-title":"The G8 frailty screening tool and the decision-making process in older breast cancer patients","volume":"30","author":"Scheepers","year":"2021","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.jgo.2023.101604_bb0045","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jgo.2023.101604_bb0055","series-title":"Geriatric assessment in oncology: G8 screening too validation and reliability study","author":"Atakul","year":"2019"},{"key":"10.1016\/j.jgo.2023.101604_bb0060","first-page":"236","article-title":"Measuring frailty: developing and testing the GFI (Groningen frailty Indicator)","volume":"41","author":"Steverink","year":"2001","journal-title":"Gerontologist"},{"key":"10.1016\/j.jgo.2023.101604_bb0065","doi-asserted-by":"crossref","first-page":"M962","DOI":"10.1093\/gerona\/59.9.M962","article-title":"Old or frail: what tells us more?","volume":"59","author":"Schuurmans","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jgo.2023.101604_bb0070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.critrevonc.2009.12.002","article-title":"Identifying an accurate pre-screening tool in geriatric oncology","volume":"75","author":"Kellen","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jgo.2023.101604_bb0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.critrevonc.2010.05.009","article-title":"Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy","volume":"79","author":"Aaldriks","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jgo.2023.101604_bb0080","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejvs.2011.07.006","article-title":"Standardised frailty indicator as predictor for postoperative delirium after vascular surgery: a prospective cohort study","volume":"42","author":"Pol","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jgo.2023.101604_bb0085","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00296-017-3868-1","article-title":"Frailty in end-stage hip or knee osteoarthritis: validation of the Groningen Frailty Indicator (GFI) questionnaire","volume":"38","author":"Meessen","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jgo.2023.101604_bb0090","article-title":"P131: testing the reliablity and validity of the \u2018Groningen Frailty Index\u2019in Turkish population","volume":"S124","author":"Ayg\u00f6r","year":"2014","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.jgo.2023.101604_bb0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jgo.2012.08.001","article-title":"Evaluation of the Groningen Frailty Indicator and the G8 questionnaire as screening tools for frailty in older patients with cancer","volume":"4","author":"Baitar","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10549-017-4523-y","article-title":"Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial","volume":"167","author":"Sonke","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2023.101604_bb0105","series-title":"Wolters Kluwer health","article-title":"PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: baseline characteristics and safety evaluation","author":"Caillet","year":"2021"},{"key":"10.1016\/j.jgo.2023.101604_bb0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2018.05.017","article-title":"Palbociclib plus endocrine therapy in older women with HR+\/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies","volume":"101","author":"Rugo","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2023.101604_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13058-020-01263-0","article-title":"Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies","volume":"22","author":"Ettl","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jgo.2023.101604_bb0120","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jnci\/djaa116","article-title":"Clinical implications of body mass index in metastatic breast cancer patients treated with Abemaciclib and endocrine therapy","volume":"113","author":"Franzoi","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2023.101604_bb0125","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1600-0609.2006.00658.x","article-title":"Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia","volume":"76","author":"Herishanu","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jgo.2023.101604_bb0130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.dsx.2014.04.009","article-title":"Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity","volume":"9","author":"Yilmaz","year":"2015","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jgo.2023.101604_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-012-2213-3","article-title":"Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review","volume":"136","author":"Carroll","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2023.101604_bb0145","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-019-05181-4","article-title":"Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population","volume":"175","author":"Clifton","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2023.101604_bb0150","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0155","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0165","article-title":"Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: a single-institution study","volume":"14","author":"[32] Agemi","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.jgo.2023.101604_bb0170","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jgo.2012.10.096","article-title":"G8 and VES-13 scores predict chemotherapy toxicity in older patients with cancer","volume":"3","author":"[33] Stokoe","year":"2012","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0175","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jgo.2022.03.004","article-title":"Prospective comparison of the value of CARG, G8, and VES-13 toxicity tools in predicting chemotherapy-related toxicity in older Turkish patients with cancer","volume":"13","author":"[34] Cavdar","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0180","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jgo.2018.10.007","article-title":"The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor","volume":"10","author":"[35] Dottorini","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2023.101604_bb0185","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jgo.2013.04.001","article-title":"Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy","volume":"4","author":"[36] Aaldriks","year":"2013","journal-title":"J Geriatr Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823002011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823002011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:59:51Z","timestamp":1761818391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406823002011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1879406823002011"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101604","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101604"}}